Shakuyaku-Kanzo-To and Heart Health
Author Information
Author(s): Muacevic Alexander, Adler John R, Tagashira Hideaki, Abe Fumiha, Sakai Ayako, Numata Tomohiro
Primary Institution: Akita University Graduate School of Medicine
Hypothesis
Does Shakuyaku-kanzo-to (SKT) prevent angiotensin II-induced cardiac hypertrophy in neonatal rat ventricular myocytes?
Conclusion
Shakuyaku-kanzo-to significantly reduces angiotensin II-induced cardiomyocyte hypertrophy and cell death.
Supporting Evidence
- SKT significantly mitigates angiotensin II-induced cardiomyocyte hypertrophy and cell death.
- SKT reduces elevated intracellular calcium levels and reactive oxygen species production.
- Co-administration of nifedipine shows that SKT antagonizes L-type calcium channel actions.
Takeaway
This study shows that a traditional Japanese medicine called Shakuyaku-kanzo-to can help protect heart cells from damage caused by a hormone that makes the heart grow too big.
Methodology
The study used neonatal rat ventricular myocytes to assess the effects of SKT on myocardial hypertrophy through various assays including immunohistochemistry and RT-PCR.
Potential Biases
Potential bias due to the use of a single traditional medicine without comparison to other treatments.
Limitations
The study was conducted in cultured cardiomyocytes, and further verification in animal models and clinical trials is needed.
Participant Demographics
Neonatal rats were used as the experimental model.
Statistical Information
P-Value
p<0.01
Statistical Significance
p<0.01
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website